The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients.

The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients. - Anagliptin effects on lipids (ANGELS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014531

Enrollment

Registered

2014-07-11

Start date

2014-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Anagliptin Anti-diabetic agents except DPP4 inhibitors

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes HbA1c >= 6.5% Serum LDL >= 120 mg/dl No DPP4 inhibitors for latest 3 months No antidiabetic medication or no change in medication for the latest 3 months 20 y.o. or older Written agreement is obtainable from the patient

Exclusion criteria

Exclusion criteria: Type 1 diabetes Treatment with insulin, glinides, high doses of SU Patients with repetitive or unaware severe hypoglycemia Severe liver diseases Patients with hemodialysis Severe cardiac diseases or acute myocardial infarction within 6 months Severe anemia Severe pancreatitis Malignant diseases Uncontrolled endocrine diseases Severe infections or surgical treatment Severe diabetic complications Severe bowel diseases Alcohol addiction Pregnant or possibly pregnant women History of allergic reaction to DPP4 inhibitors Patients who a physician-in-charge considers is unsuitable for the trial.

Design outcomes

Primary

Measure	Time frame
Blood lipid fractions	—

Countries

Japan

Contacts

Public ContactTakeshi Onoue

Nagoya University Graduate School of Medicine Department of Endocrinology and Diabetes

t-onoue@med.nagoya-u.ac.jp0527442142

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026